Objective: There is increased need for identifying the early stages of AD to help facilitate emerging treatment. There is a question as to whether Free versus Cued Recall paradigms are more effective in early diagnosis of AD. The Loewenstein-Acevedo Scales of Semantic Interference and Learning (LASSI-L) is a novel list-learning test that assesses free versus cued recall in detecting subtle changes in cognition. Method: Eighty-six older adults (71% female) with a mean age of 75.5 (SD = 7.5 years) were studied. Twenty-nine participants with amnestic mild cognitive impairment (aMCI) and 57 cognitively normal (CN) controls were administered the LASSI-L. Participants were presented with List A (15 semantically-related words: fruits, musical instruments, and clothing), followed by free and cued recall trials of the same wordlist. Following presentation of List B (a content-equivalent wordlist), a second learning trial of List A was presented, and cued recall was assessed again. Results: Free and cued recall measures of maximum storage, and vulnerability to PSI and recovery from PSI, were entered into stepwise logistic regression models. Results indicated a combination of Cued B1 (p < .005) [vulnerable to PSI] and Cued A1 (p < .005) [tapping initial learning effects] were most predictive of separating aMCI from CN groups. Using area under ROC curve, sensitivity was 62%, and specificity yielded an overall correct classification rate of 82.6%. Conclusion: When using a controlled learning paradigm with semantic retrieval cues, cued recall was far superior to free recall in differentiating aMCI from CN participants. These findings have significant implications for future research.
Cued Recall Performance on the LASSI-L, a Novel List-Learning Test, Is a Better Predictor of Early Alzheimer's Disease (AD) Than Performance on Free Recall Trials
M Gamez, A Penate, A Raffo, D Loewenstein, R Curiel, J Melo, E Crocco; A-33
Cued Recall Performance on the LASSI-L, a Novel List-Learning Test, Is a Better Predictor of Early Alzheimer's Disease (AD) Than Performance on Free Recall Trials. Arch Clin Neuropsychol 2016; 31 (6): 595. doi: 10.1093/arclin/acw043.33
Download citation file:
© 2017 Oxford University Press×